4-hydroxy-2-methoxyphenylacetic acid | 883988-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxy-2-methoxyphenylacetic acid
• 英文别名: 2-(4-hydroxy-2-methoxyphenyl)acetic acid
• CAS: 883988-36-1
• 化学式: C₉H₁₀O₄
• 分子量: 182.176
• InChiKey: GFDCLLXSQKPMIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydroxy-2-methoxyphenylacetic acid 在 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 N-(1,3-dimethyl-1H-pyrazol-4-yl)-2-[4-(6,7-dimethoxyquinolin-4-yloxy)-2-methoxyphenyl]acetamide
  参考文献：
  名称：

  Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

  摘要：

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.074
• 作为产物：
  描述：

  4-羟基-2-甲氧基苯甲醛 在 10%Pt/C 甲醇 、 sodium hydroxide 、 potassium tert-butylate 、 水 、 氢气 、 potassium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醇 、 N,N-二甲基乙酰胺 、 乙酸乙酯 为溶剂， -78.0~85.0 ℃ 、303.99 kPa 条件下， 反应 31.0h， 生成 4-hydroxy-2-methoxyphenylacetic acid
  参考文献：
  名称：

  WO2007/113548

  摘要：

  公开号：

文献信息

• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2006040520A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  这项发明涉及式(I)的喹唑啉衍生物或其药用盐、溶剂化合物或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个在描述中已定义的含义中具有任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱或与血管生成和/或血管通透性相关的疾病状态的药物的用途。
• <i>p</i>-Hydroxyphenacyl photoremovable protecting groups — Robust photochemistry despite substituent diversity
  作者：Richard S. Givens、Kenneth Stensrud、Peter G. Conrad、Abraham L. Yousef、Chamani Perera、Sanjeewa N. Senadheera、Dominik Heger、Jakob Wirz

  DOI：10.1139/v10-143

  日期：2011.2

  A broadly based investigation of the effects of a diverse array of substituents on the photochemical rearrangement of p-hydroxyphenacyl esters has demonstrated that common substituents such as F, MeO, CN, CO₂R, CONH₂, and CH₃have little effect on the rate and quantum efficiencies for the photo-Favorskii rearrangement and the release of the acid leaving group or on the lifetimes of the reactive triplet state. A decrease in the quantum yields across all substituents was observed for the release and rearrangement when the photolyses were carried out in buffered aqueous media at pHs that exceeded the ground-state pK_aof the chromophore where the conjugate base is the predominant form. Otherwise, substituents have only a very modest effect on the photoreaction of these robust chromophores.

  一项关于各种取代基对对羟基苯乙酯光化学重排影响的广泛研究表明，常见取代基（如 F、MeO、CN、CO2R、CONH2 和 CH3）对光-Favorskii 重排和酸离去基团释放的速率和量子效率影响很小，对反应三重态的寿命影响也很小。当光解在缓冲水介质中进行时，pH 值超过发色团的基态 pKao（其中共轭碱是主要形式），则释放和重排的量子产率在所有取代基中都会降低。否则，取代基对这些坚固发色团的光反应影响很小。
• Cyclic compound and ppar agonist
  申请人：Clark Richard

  公开号：US20050014833A1

  公开（公告）日：2005-01-20

  The present invention provides a novel compound having an excellent PPAR agonist action. More specifically, it provides a compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein a, b and c are the same as or different from one another and each represents 0 to 4; R 1 to R 6 are the same as or different from one another and each represents a hydrogen atom, a hydroxyl group, a cyano group, a halogen atom, etc.; A 1 and A 2 are the same as or different from each other and each represents a single bond, an oxygen atom, etc.; L, M and T each represent a single bond, an alkylene group having one to six carbon atoms, etc.; W represents a carboxyl group; the partial structure represented by the formula: represents a single bond or a double bond; X represents a single bond, an oxygen atom, —NR X1 CQ 1 O—, etc.; Y represents Y 1 —Y 2 — (wherein Y 1 represents a 5 to 14-membered aromatic ring having one to four substituents, etc.; and Y 2 represents a single bond or a 5 to 14-membered aromatic ring); and the ring Z represents a 5 to 14-membered aromatic ring which have one to four substituents selected form the above-mentioned Group A, may have one or more hetero atoms and may be partially saturated.

  本发明提供了一种具有出色PPAR激动剂作用的新化合物。更具体地说，它提供了一种由以下公式表示的化合物，其盐，酯或水合物。其中a，b和c彼此相同或不同，每个表示0到4; R1至R6彼此相同或不同，每个表示氢原子，羟基，氰基，卤素原子等; A1和A2彼此相同或不同，每个表示单键，氧原子等; L，M和T每个表示单键，具有一到六个碳原子的烷基等; W表示羧基;由以下公式表示的部分结构:表示单键或双键; X表示单键，氧原子，-NRX1CQ1O-等; Y表示Y1-Y2-（其中Y1表示具有一到四个取代基的5到14个成员的芳香环等; Y2表示单键或5到14个成员的芳香环）; 而环Z表示从上述A族中选择的具有一到四个取代基的5到14个成员的芳香环，可以具有一个或多个杂原子，并且可以部分饱和。
• Quinazoline derivatives
  申请人：Ple Patrick

  公开号：US20090233924A1

  公开（公告）日：2009-09-17

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及公式（I）的喹唑啉衍生物或其药学上可接受的盐、溶剂或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个都具有在本说明书中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们用于制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物的用途。
• QUINOLINE DERIVATIVES
  申请人：Jung Frederic Henri

  公开号：US20090076074A1

  公开（公告）日：2009-03-19

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及公式I的喹啉衍生物或其药学上可接受的盐，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有在本说明书中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于治疗细胞增殖性疾病的药物的过程中的使用。